18813-71-3

Basic information

• Product Name: 6-bromo-1-methyl-9H-beta-carboline
• CAS NO: 18813-71-3
• Molecular Formula: C₁₂H₉BrN₂
• Molecular Weight: 261.1173
• Mol File: 18813-71-3.mol

Chemical Properties

• Boiling Point: 438.2°C at 760 mmHg
• Flash Point: 218.8°C
• Density: 1.615g/cm³
• Vapor Pressure: 1.81E-07mmHg at 25°C
• Refractive Index: 1.766
• CAS DataBase Reference: 6-bromo-1-methyl-9H-beta-carboline(CAS DataBase Reference)
• NIST Chemistry Reference: 6-bromo-1-methyl-9H-beta-carboline(18813-71-3)
• EPA Substance Registry System: 6-bromo-1-methyl-9H-beta-carboline(18813-71-3)

Safety Data

• Hazardous Substances Data: 18813-71-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
6-bromo-1-methyl-9H-beta-carboline is utilized as a research compound for exploring its potential pharmacological activities, particularly its effects on the central nervous system. Its study may contribute to the development of new drugs targeting neurological conditions.
Used in Neuroscience:
6-bromo-1-methyl-9H-beta-carboline is employed in neuroscience research to investigate its role in neurodegenerative disorders. Understanding its interactions with brain receptors could provide insights into the molecular mechanisms underlying these diseases and aid in the discovery of novel therapeutic approaches.
Used in Drug Development:
6-bromo-1-methyl-9H-beta-carboline serves as a lead compound in drug development, with its specific properties and potential applications being the focus of ongoing research. Its study may pave the way for the creation of new medications with improved efficacy and safety profiles for the treatment of various neurological conditions.

Upstream product

• 102206-91-7 1-methyl-9H-β-carbolin-6-ylamine 
• 113679-50-8 6-bromo-1-methyl-2,3,4,9-tetrahydro-1H-β-carboline-3-carboxylic acid 
• 73-22-3 L-Tryptophan 
• 3156-51-2 3-[(E)-2-nitroeth-1-enyl]-1H-indole 
• 120-72-9 indole 
• 487-89-8 Indole-3-carboxaldehyde 
• 486-84-0 harmane 
• 61-54-1 tryptamine 
• 2506-10-7 eleagnine 
• 38314-91-9 6-nitro-1-methyl-9H-pyrido[3,4-b]indole 
• 6548-09-0 5-bromo-DL-tryptophan 

Downstream Products

• 1374751-67-3 6-phenyl-1-methyl-beta-carboline 
• 1374751-68-4 6-(3-chlorophenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374751-87-7 6-(3-cyanophenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374752-45-0 N-Boc-(3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)phenyl)methanamine 
• 1374752-11-0 1-ethyl-3-(3-(1-methyl-9H-pyrido[3,4-b]indol-6-yl)benzyl)urea 
• 1374751-77-5 6-(3-(acetamidomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole 
• 1374751-76-4 6-(3-(aminomethyl)phenyl)-1-methyl-9H-pyrido[3,4-b]indole 

Relevant articles and documents

Evaluation of canthinone alkaloids as cerebral protective agents

Considerable attention has been paid to cerebral protective drugs as a potential therapy for dementia. Screening of a natural compound library here resulted in identification of five canthinone alkaloids, viz., picrasidine L (1), picrasidine O (2), eurycomine E (3), 3-ethyl-canthin-5,6-dione (4), and 3-ethyl-4-methoxy-canthin-5,6-dione (5), as novel cerebral protective agents. The structure–activity relationship indicated that C-4, C-9, and N-3 substitutions greatly affected their cerebral protective effect. Among these, compound 2 exhibited a cerebral protective effect through suppressing neuronal hyperexcitability due to an increase in the excitatory neurotransmitter glutamic acid. Furthermore, compound 2 did not affect heart rate and mean systolic blood pressure. This investigation suggests that compound 2 has potential for further development as a cerebral protective drug.

Synthesis and biological evaluation of pyridazino[1′,6′:1,2]pyrido[3,4-b]indolinium and pyridazino[1,6-a]benzimidazolium salts as anti-inflammatory agents

Condensed polycyclic heteroaromatic cations bearing a bridgehead nitrogen with pyridazino[1′,6′:1,2]pyrido[3,4-b]indolinium and pyridazino[1,6-a]benzimidazolium structures were assayed as inhibitors of LPS-induced TNF-α production by THP-1 cells. The hit compound 1e, which had the best IC50 value (4.49 μM) and low toxicity, was further assayed on human PMBCs (IC50 3.91 μM) and monocytes (IC50 1.82 μM). This compound also inhibited TNF-α production following poly I:C stimulation of human monocytes and monocyte-derived dendritic cells; in the latter case, inhibition of IL-12 production was also observed. Compound 1e was also able to inhibit TNF-α expression at the transcriptional level and proved to be effective in vivo. Compound 1e is an interesting potential therapeutic agent in IMIDs.

Preparation method and application of 6-substituted-beta-carboline alkali compound and derivative

The invention relates to a preparation method and application of a 6-substituted-beta-carboline alkali compound and a derivative. The invention discloses a novel compound, namely the 6-substituted-beta-carboline alkali compound, and an application of the 6-substituted-beta-carboline alkali compound in a farm chemical bactericide. The invention also discloses the preparation method of the 6-substituted-beta-carboline alkali compound. The 6-substituted-beta-carboline alkali compound disclosed by the invention is a novel compound, has relatively good antibacterial activity and can be applied to farm chemical bactericides.

SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS

Substituted pyrido[3,4-b]indoles and their use as pharmaceuticals The present invention relates to 8-aryl-substituted and 8-heteroaryl-substituted 9H-pyrido[3,4-b]indoles of the formula I, in which A, E, G, R1 to R6 and R10 are as defined in the claims, which stimulate chondrogenesis and cartilage matrix synthesis and can be used in the treatment of cartilage disorders and conditions in which a regeneration of damaged cartilage is desired, for example joint diseases such as osteoarthritis. The invention furthermore relates to processes for the synthesis of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.

?-CARBOLINE, DIHYDRO-?-CARBOLINE AND TETRAHYDRO-?-CARBOLINE ALKALOID DERIVATIVES AND PREPARATION METHODS SAME AND USE IN ASPECTS OF PREVENTING AND TREATING PLANT VIRUSES, FUNGICIDES AND INSECTICIDES

The present invention relates to β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives (I) and a method for preparing same and the use in the aspects of preventing and treating plant viruses, fungicides and insecticides. For the meaning of each group in formula (I) see the description. The β-carboline, dihydro-β-carboline and tetrahydro-β-carboline alkaloid derivatives of the present invention show a particularly ourstanding anti-plant virus activity, and also have fungicidal and insecticidal activities.

Synthesis and antiviral and fungicidal activity evaluation of β-carboline, dihydro-β-carboline, tetrahydro-β-carboline alkaloids, and their derivatives

Six known β-carboline, dihydro-β-carboline, and tetrahydro-β-carboline alkaloids and a series of their derivatives were designed, synthesized, and evaluated for their anti-tobacco mosaic virus (TMV) and fungicidal activities for the first time. All of the alkaloids and some of their derivatives (compounds 3, 4, 14, and 19) exhibited higher anti-TMV activity than the commercial antiviral agent Ribavirin both in vitro and in vivo. Especially, the inactivation, curative, and protection activities of alkaloids Harmalan (62.3, 55.1, and 60.3% at 500 μg/mL) and tetrahydroharmane (64.2, 57.2, and 59.5% at 500 μg/mL) in vivo were much higher than those of Ribavirin (37.4, 36.2, and 38.5% at 500 μg/mL). A new derivative, 14, with optimized physicochemical properties, obviously exhibited higher activities in vivo (50.4, 43.9, and 47.9% at 500 μg/mL) than Ribavirin and other derivatives; therefore, 14 can be used as a new lead structure for the development of anti-TMV drugs. Moreover, most of these compounds exhibited good fungicidal activity against 14 kinds of fungi, especially compounds 4, 7, and 11.

Synthesis and antiviral and fungicidal activity evaluation of β-carboline, dihydro-β-carboline, tetrahydro-β-carboline alkaloids, and their derivatives

Six known β-carboline, dihydro-β-carboline, and tetrahydro-β-carboline alkaloids and a series of their derivatives were designed, synthesized, and evaluated for their anti-tobacco mosaic virus (TMV) and fungicidal activities for the first time. All of the alkaloids and some of their derivatives (compounds 3, 4, 14, and 19) exhibited higher anti-TMV activity than the commercial antiviral agent Ribavirin both in vitro and in vivo. Especially, the inactivation, curative, and protection activities of alkaloids Harmalan (62.3, 55.1, and 60.3% at 500 μg/mL) and tetrahydroharmane (64.2, 57.2, and 59.5% at 500 μg/mL) in vivo were much higher than those of Ribavirin (37.4, 36.2, and 38.5% at 500 μg/mL). A new derivative, 14, with optimized physicochemical properties, obviously exhibited higher activities in vivo (50.4, 43.9, and 47.9% at 500 μg/mL) than Ribavirin and other derivatives; therefore, 14 can be used as a new lead structure for the development of anti-TMV drugs. Moreover, most of these compounds exhibited good fungicidal activity against 14 kinds of fungi, especially compounds 4, 7, and 11.

CARBAZOLE AND CARBOLINE DERIVATIVES, AND PREPARATION AND THERAPEUTIC APPLICATIONS THEREOF

Compounds of general formula (I), wherein A, Y, R1 and R2 are defined herein are useful in the treatment or prevention of proliferative diseases including cancer or infectious or parasitic diseases.

Carbazole and carboline derivatives, and preparation and therapeutic applications thereof

Compounds of general formula (I): wherein A, R1 and R2 are defined herein are useful in the treatment or prevention of proliferative diseases including cancer.

Synthesis and cytotoxic activity of pyridazino[1′,6′:1,2]pyrido[3,4-b]indol-5-inium derivatives as anti-cancer agents

Several new pyridazino[1′,6′:1,2]pyrido[3,4-b]indol-5-inium derivatives were synthesised from β-carboline derivatives and their cytotoxic activity and effect on the cell cycle were evaluated against L1210 cancer cells.